a retrospective analysis of disease outcome in these patients who were treated with a daunorubicin or doxorubicin containing induction regimen indicated the following : ( a ) 8 of 11 patients who entered complete remission had greater than 80 % of leukemic blast cells accumulating detectable amounts of daunorubicin ;
C0013089
doxorubicin
C0011015
daunorubicin